La Jolla Pharmaceutical Company Announces Launch of GIAPREZA™ (angiotensin II) in the United States
March 22, 2018 16:01 ET
|
La Jolla Pharmaceutical Company
SAN DIEGO, March 22, 2018 (GLOBE NEWSWIRE) -- La Jolla Pharmaceutical Company (Nasdaq:LJPC) today announced that GIAPREZA™ (angiotensin II), injection for intravenous infusion, is now commercially...
La Jolla Pharmaceutical Company Announces Pricing of Public Offering of Common Stock
March 15, 2018 08:00 ET
|
La Jolla Pharmaceutical Company
SAN DIEGO, March 15, 2018 (GLOBE NEWSWIRE) -- La Jolla Pharmaceutical Company (Nasdaq:LJPC) (La Jolla), a leader in the development of innovative therapies intended to significantly improve outcomes...
La Jolla Pharmaceutical Company Announces $100 Million Public Offering of Common Stock
March 14, 2018 16:01 ET
|
La Jolla Pharmaceutical Company
SAN DIEGO, March 14, 2018 (GLOBE NEWSWIRE) -- La Jolla Pharmaceutical Company (Nasdaq:LJPC) (La Jolla), a leader in the development of innovative therapies intended to significantly improve outcomes...
GIAPREZA™ (angiotensin II) Significantly Improved Survival and Reduced Time on Renal Replacement Therapy in Patients with Acute Kidney Injury
March 06, 2018 14:40 ET
|
La Jolla Pharmaceutical Company
Analyses to Be Presented in Oral and Poster Sessions at The 23rd International Conference on Advances in Critical Care Nephrology AKI & CRRT 2018 Manuscript Published Online in Critical Care...
GIAPREZA™ (angiotensin II) Significantly Improved Survival of Patients with High APACHE II Scores in ATHOS-3 Study
February 25, 2018 09:00 ET
|
La Jolla Pharmaceutical Company
SAN DIEGO, Feb. 25, 2018 (GLOBE NEWSWIRE) -- La Jolla Pharmaceutical Company (Nasdaq:LJPC) today announced that an abstract, entitled “Effect of Disease Severity on Survival in Patients Receiving...
La Jolla Pharmaceutical Company Announces Financial Results for the Three and Twelve Months Ended December 31, 2017 and Recent Corporate Progress
February 22, 2018 17:17 ET
|
La Jolla Pharmaceutical Company
SAN DIEGO, Calif., Feb. 22, 2018 (GLOBE NEWSWIRE) -- La Jolla Pharmaceutical Company (Nasdaq:LJPC), a leader in the development of innovative therapies intended to significantly improve outcomes in...
La Jolla Pharmaceutical Company Announces the Treatment of First Patient in GIAPREZA™ (angiotensin II) Pediatric Study
February 21, 2018 09:00 ET
|
La Jolla Pharmaceutical Company
SAN DIEGO, Feb. 21, 2018 (GLOBE NEWSWIRE) -- La Jolla Pharmaceutical Company (Nasdaq:LJPC) today announced that the first pediatric patient has been treated in LJ501-CRH02, La Jolla’s open-label...
La Jolla Pharmaceutical Company Announces FDA Approval of Giapreza™ (angiotensin II)
December 21, 2017 18:15 ET
|
La Jolla Pharmaceutical Company
Giapreza increases blood pressure in adults with septic or other distributive shock La Jolla to host conference call and webcast at 8:30 a.m. EST on December 22, 2017 SAN DIEGO, Dec. 21, 2017 ...
La Jolla Pharmaceutical Company Announces Initiation of Multicenter, Randomized, Phase 2 Clinical Study of LJPC‑401 in Patients with Hereditary Hemochromatosis
December 18, 2017 09:00 ET
|
La Jolla Pharmaceutical Company
SAN DIEGO, Dec. 18, 2017 (GLOBE NEWSWIRE) -- La Jolla Pharmaceutical Company (NASDAQ:LJPC) (the Company or La Jolla) today announced the initiation of LJ401-HH01, a Phase 2 clinical study of...
La Jolla Pharmaceutical Company Announces Initiation of Pivotal Clinical Study of LJPC‑401 in Patients with Beta Thalassemia
December 04, 2017 09:00 ET
|
La Jolla Pharmaceutical Company
SAN DIEGO, Dec. 04, 2017 (GLOBE NEWSWIRE) -- La Jolla Pharmaceutical Company (NASDAQ:LJPC) (the Company or La Jolla) today announced the initiation of a pivotal clinical study of LJPC‑401 (synthetic...